# OnCo record endometrial-nsmp (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/endometrial-nsmp/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "endometrial-nsmp" ;
  schema:name "Endometrial cancer with no specific molecular profile"@en ;
  schema:alternateName "NSMP endometrial cancer"@en, "p53-wild-type, MMR-proficient, POLE-wild-type endometrial cancer"@en, "Copy-number-low endometrial cancer"@en ;
  schema:description "Endometrial cancer with no specific molecular profile is the default class: no POLE mutation, intact mismatch repair and normal p53. Most are low-grade, oestrogen-driven tumours cured by hysterectomy, and hormone-blocking drugs are their most natural treatment when they do recur."@en ;
  schema:url <https://onco.cc/cancers/endometrial-nsmp/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/endometrial-p53-abnormal/>, <https://onco.cc/cancers/endometrial-pole-ultramutated/>, <https://onco.cc/cancers/uterine-carcinosarcoma/> ;
  onco:terms <https://onco.cc/terms/nsmp/>, <https://onco.cc/terms/pten-loss/>, <https://onco.cc/terms/depth-of-invasion/>, <https://onco.cc/terms/mlh1-promoter-methylation/> ;
  onco:trials <https://onco.cc/trials/portec-2/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nrg-gy018-nejm-2023/>, <https://onco.cc/key-papers/paper-promise-talhouk-cancer-2017/>, <https://onco.cc/key-papers/paper-portec-2-lancet-2010/>, <https://onco.cc/key-papers/paper-esgo-estro-esp-endometrial-concin-ijgc-2021/> ;
  onco:pipeline <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/>, <https://onco.cc/trials/xport-ec-042/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:standardOfCare <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/fires-sentor/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/technologies/fertility-sparing-endometrial/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/trials/nrg-gy018-keynote-868/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-775/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/abemaciclib/> .